Statins
Verified · Oct 2026Block HMG-CoA reductase, and the liver cell answers with more LDL receptors — the receptors, not the lost synthesis, are what pull LDL out of the blood. How much statin reaches muscle depends on CYP3A4 and the hepatic uptake transporter OATP1B1 (SLCO1B1).
Nursing view → administration, monitoring and patient teaching
Compare: Lipid-lowering agents compared →
Drugs
Mechanism
Competitively inhibit HMG-CoA reductase, the rate-limiting enzyme of hepatic cholesterol synthesis — upregulating LDL receptors and lowering circulating LDL; also stabilize atherosclerotic plaque.
HMG-CoA reductase: the committed step
In the smooth ER, HMG-CoA reductase reduces HMG-CoA to mevalonate — the key rate-limiting, committed step of cholesterol synthesis; mevalonate then passes through isopentenyl pyrophosphate, farnesyl pyrophosphate, squalene and lanosterol. Statins are competitive inhibitors of this enzyme.
Two statins are given as inactive lactone prodrugs: simvastatin and lovastatin are hydrolysed after administration to their active β-hydroxyacid forms. Atorvastatin is active as given, and its hydroxylated metabolites inhibit the enzyme as strongly as the parent — about 70% of its circulating inhibitory activity comes from active metabolites.
SREBP and the LDL receptor — why LDL falls
LDL receptors on hepatocytes determine plasma LDL: LDL binds the receptor, and the complex is taken in through clathrin-coated pits. When a cell senses that its cholesterol has fallen, the transcription factor SREBP moves from the endoplasmic reticulum to the Golgi, is cleaved and activated by proteases, travels to the nucleus and increases LDL-receptor expression. More receptors mean more LDL taken up from the blood.
That is why a statin’s LDL-lowering depends on functioning receptors. In homozygous familial hypercholesterolemia, where LDL receptors are absent, lovastatin is less effective — possibly, the label says, because these patients have no functional LDL receptors.
Lipophilic or hydrophilic, CYP3A4 or not
Lipophilic statins — atorvastatin, simvastatin and lovastatin — are absorbed faster and enter cells by passive diffusion, distributing widely. Hydrophilic statins — pravastatin and rosuvastatin — sit at the polar cell surface and need transporter proteins to reach the enzyme. The hepatic uptake transporter OATP1B1 (encoded by SLCO1B1) handles atorvastatin, rosuvastatin, simvastatin and pravastatin.
CYP3A4 is central to the metabolism of atorvastatin, lovastatin and simvastatin, so strong CYP3A4 inhibitors and grapefruit juice raise their levels. Rosuvastatin clearance does not depend on CYP3A4 to a clinically significant extent (about 10% becomes metabolite, mainly by CYP2C9), and pravastatin is handled by isomerisation and ring hydroxylation rather than CYP3A4 — but both depend on transporters, so OATP1B1 inhibitors such as cyclosporine raise their levels.
Why muscle suffers — exposure and mitochondria
The risk of myopathy rises with the level of HMG-CoA reductase inhibitory activity in plasma, so anything that raises exposure raises risk: high doses, CYP3A4 or OATP1B1 inhibitors, age 65 or older, uncontrolled hypothyroidism and renal impairment. Reduced SLCO1B1 function cuts hepatic uptake — simvastatin acid exposure rises, and myopathy risk with it.
Proposed cellular mechanisms include coenzyme Q10 depletion causing mitochondrial dysfunction, disrupted cellular respiration, impaired calcium homeostasis and apoptosis. A distinct, rare autoimmune form — immune-mediated necrotizing myopathy — carries anti-HMG-CoA reductase antibodies and persists after the statin is stopped. At the extreme, muscle breakdown releases myoglobin and causes rhabdomyolysis with acute kidney injury.
Comparing the drugs
Statin properties
| Drug | Solubility | Main metabolism | Active form | Half-life | Dosing time (label) |
|---|---|---|---|---|---|
| Atorvastatin | Lipophilic | CYP3A4; OATP1B1 substrate | Active, with active metabolites (about 70% of activity) | About 14 h (inhibitory activity 20–30 h) | Any time of day, with or without food |
| Rosuvastatin | Hydrophilic | Little metabolism (about 10%, CYP2C9); OATP1B1 and BCRP | Active | About 19 h | Any time of day, with or without food |
| Simvastatin | Lipophilic | CYP3A4; acid is an OATP1B1 substrate | Lactone prodrug → simvastatin acid | Total radioactivity (drug + metabolites) about 10% of peak by 12 h | Evening |
| Pravastatin | Hydrophilic | Isomerisation and ring hydroxylation (not CYP3A4); OATP1B1 | Active as given | About 2.6–3.2 h | Any time of day, with or without food |
| Lovastatin | Lipophilic | CYP3A4 | Lactone → β-hydroxyacid | Total radioactivity (drug + metabolites) about 10% of peak by 24 h | With meals (start with the evening meal) |
What raises exposure — and the label specifics
| Drug | Strong CYP3A4 inhibitors / grapefruit | OATP1B1 inhibitors (e.g. cyclosporine) | Notable label point |
|---|---|---|---|
| Atorvastatin | Raise levels | Raise levels | Hepatic uptake by OATP1B1; metabolites also OATP1B1 substrates |
| Rosuvastatin | Not clinically significant | Raise levels | About 2-fold higher exposure in Asian patients; proteinuria/hematuria reported |
| Simvastatin | Contraindicated (strong inhibitors) | Raise levels | Taken in the evening; suspend during unavoidable strong-inhibitor courses |
| Pravastatin | Not a CYP3A4 issue | Raise levels significantly | Dose limits with cyclosporine and select macrolides |
| Lovastatin | Contraindicated (strong inhibitors); grapefruit raises exposure | Cyclosporine — avoid | Old-format label still contraindicates pregnancy and nursing |
Pharmacokinetics
- Atorvastatin — atorvastatin
- Low systemic availability from gut-wall and hepatic first-pass clearance; at least 98% protein-bound. Extensively metabolised (CYP3A4) to active hydroxylated derivatives and eliminated mainly in bile. Half-life about 14 hours, but inhibitory activity lasts 20–30 hours because of active metabolites.
- Rosuvastatin — rosuvastatin
- Hydrophilic and not extensively metabolised (about 10% recovered as metabolite, chiefly N-desmethyl rosuvastatin via CYP2C9); about 90% excreted in feces; half-life about 19 hours. Exposure is roughly doubled in Asian subjects.
- Simvastatin and lovastatin — simvastatin, lovastatin
- Lactone prodrugs hydrolysed to their active β-hydroxyacids; both are highly protein-bound and CYP3A4 substrates. Lovastatin levels when fasting are about two-thirds of fed levels, so it is taken with meals.
- Pravastatin — pravastatin
- Given in active form; oral bioavailability about 17% after extensive hepatic first-pass extraction; a relatively polar, hydrophilic compound. About 47% of total clearance is renal, and about 20% of an oral dose appears in urine. Half-life about 2.6–3.2 hours.
- Transporters
- OATP1B1 takes atorvastatin, rosuvastatin, simvastatin, pitavastatin and pravastatin into hepatocytes. Inhibitors of OATP1B1 (for example cyclosporine) raise statin exposure even for statins that bypass CYP3A4.
- Dosing time
- Hepatic cholesterol synthesis is highest in the early morning, which is the rationale for evening dosing of short-acting statins; simvastatin is labelled for evening use, lovastatin for meals, and pravastatin and rosuvastatin for any time of day.
Pharmacogenomics
Uses & drug choice
- Hyperlipidemia (elevated LDL cholesterol)
- Primary & secondary prevention of atherosclerotic cardiovascular disease (ASCVD)
Adverse effects
- Myalgia, myopathy, rhabdomyolysis
- Risk tracks plasma inhibitory activity — dose, CYP3A4 or OATP1B1 inhibitors, reduced SLCO1B1 function, age 65 or older, uncontrolled hypothyroidism and renal impairment. Proposed cellular mechanisms: coenzyme Q10 depletion with mitochondrial dysfunction, impaired calcium homeostasis and apoptosis. Released myoglobin and other muscle contents can cause acute kidney injury.
- Immune-mediated necrotizing myopathy (rare)
- An autoimmune myopathy with anti-HMG-CoA reductase antibodies: proximal weakness and high CK persist after the statin is stopped and improve with immunosuppression.
- Liver-enzyme rises
- Usually transient, appearing soon after starting and resolving on continued therapy or a brief interruption; persistent rises above 3× ULN occur in a small percentage, and hepatic failure is rare. The liver is the main site of statin action and clearance.
- Rosuvastatin: proteinuria and hematuria
- Dipstick-positive proteinuria and microscopic hematuria were seen in trials; the clinical significance is unknown, and a dose reduction is considered if they persist without explanation.
Toxicity & antidote
Rhabdomyolysis is the breakdown of skeletal muscle with release of myoglobin, creatine kinase, electrolytes and sarcoplasmic proteins into the blood. It presents with myalgia, weakness and dark urine from myoglobinuria, and it can cause acute kidney injury, electrolyte disturbance and disseminated intravascular coagulation; early hydration helps prevent renal damage.
For statins, the labels define myopathy as muscle symptoms with CK above 10 times the upper limit of normal. The statin is stopped when CK is markedly elevated or myopathy is suspected, and it is withheld temporarily in states that predispose to rhabdomyolysis-related renal failure, such as sepsis, shock, major surgery or trauma.
Interactions
Contraindications
- Acute liver failure or decompensated cirrhosis — Impaired hepatic clearance raises statin levels (myopathy risk), and the drug can further stress an already-injured liver.
- Pregnancy (stop when recognized) and breastfeeding (not recommended) use caution — Cholesterol is needed for fetal development, and pausing lipid-lowering for a pregnancy should have little effect on the long-term outcome. (In 2021 the FDA removed the blanket contraindication, but statins are still discontinued for most pregnant patients — and current lovastatin labels still list pregnancy and breastfeeding as contraindications.)
- Lovastatin: active liver disease or unexplained persistent transaminase elevations; strong CYP3A4 inhibitors; pregnancy or breastfeeding — Labeled contraindications for lovastatin: it is a CYP3A4 substrate, so strong inhibitors raise its level and myopathy risk, and its label still contraindicates use in pregnancy and nursing.
- Strong CYP3A4 inhibitors / fibrates / grapefruit (with certain statins) use caution — These raise the blood level of simvastatin, lovastatin and atorvastatin, pushing myopathy and rhabdomyolysis risk up — use an alternative statin or avoid the combination. Pravastatin is not a CYP3A4 problem but is a substrate of the transporter OATP1B1, so OATP1B1 inhibitors (for example cyclosporine) raise its level.
High-yield
- A — Atorvastatin
- L — Lovastatin
- S — Simvastatin
- These three depend on CYP3A4, so strong inhibitors and grapefruit raise their levels; pravastatin and rosuvastatin do not
- P — pravastatin and R — rosuvastatin are the hydrophilic statins
- Swim — instead of diffusing through membranes like the lipophilic statins, they need transporters (OATP1B1) to enter cells
- Water-loving and CYP3A4-independent — but OATP1B1 inhibitors such as cyclosporine still raise their levels
Practice questions
Q1A 52-year-old man starts a statin. Six weeks later his plasma LDL has fallen substantially, although his hepatic cholesterol synthesis is only partly suppressed.
Which change best explains most of the fall in plasma LDL?
- A.Decreased intestinal cholesterol absorption
- B.Inhibition of lipoprotein lipase
- C.Inhibition of PCSK9 synthesis
- D.Increased bile-acid excretion
- E.SREBP-driven increase in hepatocyte LDL receptors
Show answer
E. SREBP-driven increase in hepatocyte LDL receptors — Lower intracellular cholesterol activates SREBP, which moves from the ER to the Golgi, is cleaved and enters the nucleus to increase LDL-receptor expression. More hepatic LDL receptors take up LDL from the blood — LDL receptors on the liver determine plasma LDL.
Q2A 60-year-old man on simvastatin develops diffuse muscle pain and dark urine a week after starting clarithromycin. CK is 40 times the upper limit of normal.
What best explains this reaction?
- A.Clarithromycin directly damages muscle
- B.Simvastatin induces CYP3A4
- C.An immune-mediated necrotizing myopathy triggered by the antibiotic
- D.CYP3A4 inhibition raised simvastatin exposure
- E.Hypothyroidism caused by clarithromycin
Show answer
D. CYP3A4 inhibition raised simvastatin exposure — Simvastatin is a CYP3A4 substrate; strong CYP3A4 inhibitors such as clarithromycin increase simvastatin exposure and the risk of myopathy and rhabdomyolysis, which is why they are contraindicated together. Myopathy risk rises with the plasma level of HMG-CoA reductase inhibitory activity. Immune-mediated necrotizing myopathy is different: a rare autoimmune myopathy associated with statin use itself, with anti-HMG-CoA reductase antibodies and weakness that persists after the statin is stopped.
Q3A 45-year-old woman with HIV on a protease-inhibitor regimen needs LDL lowering.
Which statin is least affected by her antiretroviral therapy’s CYP3A4 inhibition?
- A.Rosuvastatin
- B.Simvastatin
- C.Lovastatin
- D.Atorvastatin
- E.All statins are equally affected
Show answer
A. Rosuvastatin — Rosuvastatin clearance does not depend on CYP3A4 to a clinically significant extent (about 10% is metabolised, mainly by CYP2C9). Simvastatin and lovastatin are contraindicated with strong CYP3A4 inhibitors such as HIV protease inhibitors, and atorvastatin levels rise. Transporter interactions still need checking.
Q4Pharmacogenomic testing in a patient who developed myalgia on simvastatin shows two decreased-function alleles of the gene encoding the hepatic OATP1B1 transporter.
What is the gene, and what is its effect?
- A.CYP2C19 — slower simvastatin activation
- B.HMGCR — a resistant enzyme
- C.SLCO1B1 — reduced hepatic uptake and higher simvastatin acid exposure
- D.ABCG2 — increased biliary excretion
- E.CYP3A5 — faster simvastatin clearance
Show answer
C. SLCO1B1 — reduced hepatic uptake and higher simvastatin acid exposure — SLCO1B1 encodes OATP1B1. Poor function raises simvastatin acid exposure and highly increases myopathy risk; CPIC (level A) recommends an alternative statin. ABCG2 matters for rosuvastatin.
Q5An 8-year-old with LDL cholesterol near 1000 mg/dL from a homozygous LDL-receptor mutation has a poor response to a statin.
Why do statins work poorly in this child?
- A.Excess intestinal cholesterol absorption
- B.Absent functional LDL receptors, so statin-induced receptor upregulation cannot occur
- C.Rapid CYP3A4 metabolism of statins in children
- D.Mutated HMG-CoA reductase that statins cannot bind
- E.Antibodies against the statin
Show answer
B. Absent functional LDL receptors, so statin-induced receptor upregulation cannot occur — A homozygous LDL-receptor mutation leaves no receptors on hepatocytes, raising LDL to around 1000 mg/dL. Statins lower LDL mainly by upregulating LDL receptors, so the lovastatin label notes reduced effectiveness in homozygous familial hypercholesterolemia, possibly because these patients have no functional LDL receptors. Statins still competitively inhibit HMG-CoA reductase, but the receptor upregulation that follows has no receptors to act on — so the problem lies in the LDL receptor named in the stem, not in statin absorption, metabolism, enzyme binding or antibodies.
Sources
- Atorvastatin — adverse effects, myopathy, contraindications — StatPearls (NCBI)
- Ezetimibe — NPC1L1 cholesterol-absorption inhibition, ~13–20% LDL reduction (non-statin note) — StatPearls (NCBI)
- PCSK9 Inhibitors — alirocumab/evolocumab/inclisiran, up to ~60% LDL reduction (non-statin note) — StatPearls (NCBI)
- Fibric Acid Antilipemic Agents — PPAR-α, triglyceride lowering, statin-combination myopathy risk — StatPearls (NCBI)
- Lipitor (atorvastatin) — current FDA label: contraindications, myopathy, hepatic testing, pregnancy — FDA / DailyMed
- Crestor (rosuvastatin) — FDA label — FDA / DailyMed
- Zocor (simvastatin) — FDA label: evening dosing, CYP3A4 and gemfibrozil contraindications, grapefruit — FDA / DailyMed
- Zetia (ezetimibe) — FDA label — FDA / DailyMed
- Statin Medications — mechanism, dosing time, monitoring, interactions — StatPearls (NCBI)
- Biochemistry, Cholesterol — synthesis and the rate-limiting HMG-CoA reductase step — StatPearls (NCBI)
- Atherosclerosis — LDL, foam cells, plaque rupture and thrombosis — StatPearls (NCBI)
- Rhabdomyolysis — myoglobin, kidney injury, CK thresholds — StatPearls (NCBI)
- Liver Function Tests — typical ALT/AST reference ranges — StatPearls (NCBI)
- Simvastatin — evening dosing, grapefruit, myopathy — StatPearls (NCBI)
- The use of stems in the selection of International Nonproprietary Names (-vastatin, -mab) — World Health Organization
- Biochemistry, LDL Cholesterol — LDL receptors set plasma LDL — StatPearls (NCBI)
- Pravastatin sodium tablets (Aurobindo) — FDA label: OATP1B1 interactions, any-time dosing, myopathy and hepatic warnings — FDA / DailyMed
- Lovastatin tablets (Lupin) — FDA label: contraindications, CYP3A4 interactions, take with meals — FDA / DailyMed
- Pravastatin — mechanism, LDL-receptor upregulation — StatPearls (NCBI)
- CPIC guideline: SLCO1B1, ABCG2, CYP2C9 and statins (CPIC API) — CPIC
- Table of Pharmacogenomic Biomarkers in Drug Labeling — U.S. FDA
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.